CANCERVIH
Le collectif de soins, d'enseignement et de recherche dédié aux personnes vivant avec le VIH et atteintes d'un cancer.
Accueil > Publications scientifiques
Les publications scientifiques du collectif CANCERVIH
Retrouvez l'ensemble des articles et travaux scientifiques issus des recherches menées ou soutenues par le collectif CANCERVIH. Cette page recense nos contributions majeures visant à optimiser les pratiques cliniques et améliorer la prise en charge des patients.
Les liens ci-dessous vous redirigent directement vers les publications originales et leurs résumés dans les revues de référence.
SARS-CoV-2 lineage-dependent temporal phylogenetic distribution and viral load in immunocompromised and immunocompetent individuals.
Zafilaza K, Fauchois A, Leducq V, Coppée R, Guilbaud R, Yusti AF, Todesco E, Bridier-Nahmias A, Hingrat QL, Choquet S, Cacoub P, Amoura Z, Barrou B, Pourcher V, Spano JP, Louet M, Kramer L, Goulenok T, Salpin M, Daugas E, Dorent R, Ottaviani S, Zalcman G, Ghosn J, Charpentier C, Descamps D, Marcelin AG, Calvez V, Ferre VM, Marot S, Soulie C.
Virol J. 2025 Apr 25;22(1):1185.
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, Meher Ben Abdelghani, Federica Morano, Amitesh Roy, Laetitia Dahan, Stefano Tamberi, Amandeep Singh Dhadda, Mark P Saunders, Nathalie Casanova, Rosine Guimbaud, Astrid Lievre, Joan Maurel, Marwan Fakih, Chuan Tian, Jill Harrison, Mark M Jones, Mark Cornfeld, Jean-Philippe Spano, Pauline Rochefort, for the POD1UM-303/InterAACT-2 study investigators.
The Lancet. Volume 405, Issue 10495. p2144-2152. June 14, 2025.
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC.
Abbar B, Labreche K, Cadranel J, Veyri M, Morin V, Thiam FS, Desire N, Baron M, Guillerm E, Perrier A, Fallet V, Maitre T, Canellas A, Tarantino N, Mze O, Samri A, Dejancourt L, Nakid-Cordero C, Vozy A, Picca A, Touat M, Guihot A, Chouaid C, Mokhtari K, Bielle F, Brocheriou I, Rouvier P, Osorio AR, Buob D, Bouzidi A, Marie Y, Assouad J, Boelle PY, Coulet F, Vieillard V, Spano JP, Autran B.
J Thorac Oncol. 2025 Jul;20(7):897-911.
Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites.
Guiraud V, Fauchois A, Soulie C, Leducq V, Veyri M, Assoumou L, Boutolleau D, Costagliola D, Lambotte O, Spano JP, Pourcher V, Marcelin AG, Calvez V.
Sci Rep. 2025 Aug 28;15(1):31726.
Projecting changes in demographics and causes of death in people with HIV in western Europe from 2025 to 2050: a mathematical modelling study.
Ambia J, van Sighem A, Pantazis N, Gill MJ, Grabar S, Monforte AD, Zangerle R, Bruguera A, Teira R, Jarrin I, Vehreschild J, Cavassini M, van der Valk M, Bonnet F, Sterne JAC, Ingle SM, Trickey A.
Lancet HIV. 2025 Nov 7:S2352-3018(25)00197-3.
Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study.
de Givry AC, Manchon P, Veyri M, Delyon J, Malissen N, Gaudy-Marqueste C, Zehou O, Jannic A, Gérard E, Kramkimel N, Longvert C, Maubec E, Boileau M, Stoebner PE, Montaudié H, Quéreux G, L'Orphelin JM, Poirier E, Girard C, Nardin C, Mortier L, Ferré VM, Descamps V, Spano JP, Laouenan C, Ghosn J, Lebbé C, Brunet Possenti F.
Oncologist. 2025 Dec 15:oyaf419.
Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV.
Grabar S, Lakrout P, Potard V, Belot A, Cadranel J, Jacomet C, Katlama C, Marshall E, Lambotte O, Palich R, Ronot-Brégigeon S, Spano JP, Bouvier AM, Makinson A, Costagliola D.
Int J Cancer. 2025; 1-11.